ADVFN US – Market Content Editor

Vera Therapeutics, Inc. (NASDAQ:VERA) saw its stock soar by 80% following the announcement of encouraging data from its ORIGIN Phase 3 trial evaluating atacicept, a potential treatment for immunoglobulin A nephropathy (IgAN). The trial demonstrated that atacicept significantly reduced proteinuria – a key marker of kidney damage – by 46% from baseline and 42% versus…

Meta Platforms (NASDAQ:META), the parent company of Facebook and Instagram, is reportedly advancing plans to enable fully automated ad creation and delivery through artificial intelligence by the end of 2026, according to a Wall Street Journal report citing company sources. The tech giant, whose social apps serve a combined 3.43 billion unique users globally, is…

Campbell Soup Company (NYSE:CPB) exceeded Wall Street’s expectations in its fiscal third-quarter earnings report, buoyed by the integration of Sovos Brands and a rebound in at-home food consumption across income levels. The company reported adjusted earnings per share of $0.73, outpacing the consensus forecast of $0.65. Revenue came in at $2.48 billion, a 4% increase…

French pharmaceutical giant Sanofi has officially agreed to acquire Blueprint Medicines Corp. for a significant sum of $9.1 billion. This move aligns with Sanofi’s strategy to bolster its presence in the field of rare immunological diseases. The announcement was made by Bloomberg on June 2, 2025. Under the terms of the agreement, Sanofi will pay…

DraftKings (NASDAQ:DKNG) saw its stock tumble by 5% on Monday, while Flutter Entertainment (NYSE:FLUT), the parent company of FanDuel, fell 3.3% after Illinois passed a new tax structure that could significantly increase costs for major online sportsbook operators. The changes came as a surprise over the weekend with the passage of the state’s fiscal year…

Lyra Therapeutics (NASDAQ:LYRA) saw its stock soar by 180% after releasing encouraging Phase 3 results for its lead investigational product, LYR-210, a bioabsorbable nasal implant intended to treat chronic rhinosinusitis (CRS). The company’s pivotal ENLIGHTEN 2 trial met its main goal, showing statistically significant symptom relief in patients. The study confirmed that LYR-210 provided meaningful…

Morgan Stanley has reaffirmed its Overweight rating on Nvidia (NASDAQ:NVDA), describing the company as a rare and compelling investment in the semiconductor industry. Despite sector-wide concerns and looming headwinds, the firm continues to rank Nvidia as its top pick. “This still appears to us as an exceptional investment scenario,” analysts at Morgan Stanley noted in…

BioNTech SE (NASDAQ:BNTX) and Bristol Myers Squibb (NYSE:BMY) have unveiled a sweeping global alliance to jointly develop and commercialize BioNTech’s bispecific antibody candidate, BNT327. Designed to treat a range of solid tumors, BNT327 targets two key proteins – PD-L1 and VEGF-A – known to play pivotal roles in cancer growth and immune evasion. This collaboration,…

The major U.S. index futures on the Dow Jones, S&P and Nasdaq are currently pointing to a lower open on Monday, with stocks likely to move to the downside after ending last Friday’s volatile session little changed. Renewed trade concerns are likely to weigh on the markets amid further signs of rising tensions between the…

In a recent client note, RBC Capital updated its year-end 2025 target for the S&P 500 to 5,730, a modest increase from their previous projection of 5,550. However, the firm cautions that despite this higher target, the index is still likely to experience a decline from current levels before the year closes. RBC analysts described…